Vertex seeks to mobilise Sh5 billion for the Bond Fund through the issuance of 50 million units, and a further Sh5 billion ...

Pharma Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia By Kevin Dunleavy Jan 16, 2024 3:40pm CRISPR Vertex Pharmaceuticals FDA Casgevy (exa-cel) ...

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes – Vertex to initiate a Phase 1/2 ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-deri ...

Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.